Moderna Change in Accounts Receivable 2017-2025 | MRNA

Moderna change in accounts receivable for the twelve months ending June 30, 2025 was $452M, a 69.79% decline year-over-year.

  • Moderna annual change in accounts receivable for 2024 was $0.534B, a 8.32% increase from 2023.
  • Moderna annual change in accounts receivable for 2023 was $0.493B, a 72.46% decline from 2022.
  • Moderna annual change in accounts receivable for 2022 was $1.79B, a 200.34% decline from 2021.

Moderna Change in Accounts Receivable 2017-2025 | MRNA

  • Moderna annual change in accounts receivable for 2024 was $0.534B, a 8.32% increase from 2023.
  • Moderna annual change in accounts receivable for 2023 was $0.493B, a 72.46% decline from 2022.
  • Moderna annual change in accounts receivable for 2022 was $1.79B, a 200.34% decline from 2021.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$248.3B
Amgen (AMGN)$155.9B
Gilead Sciences (GILD)$142.4B
Vertex Pharmaceuticals (VRTX)$99.3B
Bristol Myers Squibb (BMY)$96.1B
GSK (GSK)$81.1B
CSL (CSLLY)$67.7B
Regeneron Pharmaceuticals (REGN)$62.3B
Alnylam Pharmaceuticals (ALNY)$59.1B
Argenex SE (ARGX)$43.3B
Insmed (INSM)$27.9B
BioNTech SE (BNTX)$25.2B
Royalty Pharma (RPRX)$21B
Biogen (BIIB)$20B
Incyte (INCY)$16.4B
Genmab (GNMSF)$16B
Genmab (GMAB)$15.7B
Illumina (ILMN)$15.2B
Ascendis Pharma (ASND)$12B
BioMarin Pharmaceutical (BMRN)$11B
Swedish Orphan Biovitrum (BIOVF)$10.9B
QIAGEN (QGEN)$10.9B
Exelixis (EXEL)$10.3B
Verona Pharma American Depositary Share (VRNA)$9.1B
Bio-Techne Corp (TECH)$8.9B
Exact Sciences (EXAS)$8.7B
Halozyme Therapeutics (HALO)$8.5B
Blueprint Medicines (BPMC)$8.3B
Roivant Sciences (ROIV)$8.1B
Guardant Health (GH)$7.9B